Navigation Links
Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement
Date:3/24/2011

SUNNYVALE, Calif., March 24, 2011 /PRNewswire/ -- Molecular Devices, Inc. and ChanTest Corporation, leading providers of ion channel and GPCR drug discovery tools and solutions, have signed an agreement for Molecular Devices to distribute ChanTest's extensive portfolio of ion channel and GPCR cell lines on a non-exclusive basis.  As part of the agreement, Molecular Devices, Inc. will sell ChanTest's ion channel and GPCR cell lines and promote ChanTest's cell optimization services to its PatchXpress® 7000A, IonWorks® Quattro, IonWorks Barracuda™ and FLIPR® Tetra system customers worldwide. ChanTest has a portfolio of more than 145 ion channel and 110 GPCR cell lines.

(Logo:  http://photos.prnewswire.com/prnh/20100406/SF82092LOGO)

Mark Verheyden, President or Molecular Devices, Inc. said: "Customers have asked us in the past for validated cell lines optimized for our systems. ChanTest has optimized and validated their cell lines on our PatchXpress 7000A, IonWorks Quattro, IonWorks Barracuda, or IonWorks Quattro and IonWorks Barracuda and FLIPR® Tetra systems, so our customers can be confident that cell lines from ChanTest Corporation will perform well in their assays. By teaming up with the ChanTest Corporation, we are able to provide our customers a complete end-to-end solution for their ion channel and GPCR assays."

Dr. Arthur Brown, founder  of ChanTest said: "Molecular Devices, Inc. with its full line of automated electrophysiology and GPCR screening instrumentation is an exceptional partner. Providing more high quality options to a larger group of customers naturally will bring more visibility to our best-in-class ion channel cell lines and complement them perfectly. We look forward to providing their customers with ion channel- and GPCR-expressing cell lines that we have validated and optimized for their instruments. The ability to screen ion channels with automated electrophysiology is revolutionizing drug discovery."

About Molecular Devices, Inc.

At Molecular Devices we have one focus—our customers. Whether a long-time user, recent adopter, or prospective customer, your needs fuel our actions. We hire creative, best-in-class people to design, manufacture, and commercialize analytical instruments, software, and assays as well as provide dedicated follow-on support. Understanding your laboratory workflow is our top priority, and we direct product development toward solving your unique issues. Our instruments offer a full spectrum of detection technologies and meet all throughput needs—from dedicated, single-readout devices to multi-readout systems. Our goal is to deliver highly relevant analytical products to detect biology, decode data, and drive discovery. With headquarters in Silicon Valley and offices around the globe, we support and enrich efforts of the international BioResearch, BioPharma, and BioTesting communities. Visit us today at www.MolecularDevices.com.

Molecular Devices products are for Research Use Only. Not for use in diagnostic procedures.

Molecular Devices, the Molecular Devices logo, and all other trademarks are the property of Molecular Devices, Inc.

About ChanTest Corporation (www.chantest.com)

ChanTest's mission is to serve the research, drug discovery, and drug development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company's library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest's seminal role in the pre-clinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.


'/>"/>
SOURCE Molecular Devices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics to Acquire Celera, Strengthening Position as Worlds Leading Innovator in Molecular Diagnostics and Development
2. New Technologies Open the Door for Low Dose Breast-Specific Gamma Imaging (BSGI) / Molecular Breast Imaging (MBI)
3. DNA Direct Announces New Health Plan Clients Managing Molecular Diagnostic and Genetic Tests
4. Intelligent Medical Devices, Inc. (IMDx) Enters into an Agreement with Abbott for the Distribution of a Broad Menu of Molecular Tests
5. Caliper and Seegene Partner to Provide Innovative Multiplex Molecular Diagnostics Products
6. New Amplified Molecular Tests Promise to Help Improve Diagnosis and Treatment of Herpes Patients
7. Reportlinker Adds Molecular Diagnostics in Cancer Testing
8. WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System
9. Joseph Perrone Joins SRI International to Direct Molecular Diagnostics and Rare and Neglected Diseases Group
10. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology:
(Date:4/28/2017)... LINCOLN, R.I. (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much ... Sleep Foundation (NSF), going just 19 hours without sleep can compromise motor reaction time, which ... Awareness Week, and Amica Insurance is sharing the following tips from the NSF to help ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: ... , “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on ... and Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management Association (RBMA) ... 2017-2018. The annual board election process has been in place since the RBMA was ... C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):